JP2013524213A - 炎症をもたらす組織分解を検出する方法 - Google Patents
炎症をもたらす組織分解を検出する方法 Download PDFInfo
- Publication number
- JP2013524213A JP2013524213A JP2013502539A JP2013502539A JP2013524213A JP 2013524213 A JP2013524213 A JP 2013524213A JP 2013502539 A JP2013502539 A JP 2013502539A JP 2013502539 A JP2013502539 A JP 2013502539A JP 2013524213 A JP2013524213 A JP 2013524213A
- Authority
- JP
- Japan
- Prior art keywords
- comp
- sample
- complement
- complex
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008354 tissue degradation Effects 0.000 title claims abstract description 12
- 230000004054 inflammatory process Effects 0.000 title description 15
- 206010061218 Inflammation Diseases 0.000 title description 13
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000000295 complement effect Effects 0.000 claims abstract description 33
- 239000012634 fragment Substances 0.000 claims abstract description 31
- 238000003556 assay Methods 0.000 claims abstract description 27
- 238000006731 degradation reaction Methods 0.000 claims abstract description 16
- 230000024203 complement activation Effects 0.000 claims description 36
- 210000002966 serum Anatomy 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 210000001179 synovial fluid Anatomy 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 10
- 101000725508 Homo sapiens Cartilage oligomeric matrix protein Proteins 0.000 claims description 7
- 102000050578 human COMP Human genes 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 6
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 6
- 208000000491 Tendinopathy Diseases 0.000 claims description 6
- 210000002808 connective tissue Anatomy 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 5
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 5
- 206010043255 Tendonitis Diseases 0.000 claims description 5
- 201000004415 tendinitis Diseases 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 206010061818 Disease progression Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 201000002661 Spondylitis Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000005750 disease progression Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000006378 damage Effects 0.000 abstract description 5
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 230000028709 inflammatory response Effects 0.000 abstract description 3
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 48
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 description 47
- 206010039073 rheumatoid arthritis Diseases 0.000 description 25
- 239000000523 sample Substances 0.000 description 17
- 201000008482 osteoarthritis Diseases 0.000 description 14
- 210000000845 cartilage Anatomy 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000004154 complement system Effects 0.000 description 8
- 208000012659 Joint disease Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 108010005642 Properdin Proteins 0.000 description 6
- 102100038567 Properdin Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 206010023203 Joint destruction Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 102000002938 Thrombospondin Human genes 0.000 description 3
- 108060008245 Thrombospondin Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008355 cartilage degradation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000004074 complement inhibitor Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 102000004427 Collagen Type IX Human genes 0.000 description 1
- 108010042106 Collagen Type IX Proteins 0.000 description 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 102000007604 Complement C3b Inactivator Proteins Human genes 0.000 description 1
- 108010007152 Complement C3b Inactivator Proteins Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000038019 Juvenile systemic sclerosis Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 1
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 208000023835 Tendon disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 108010052926 complement C3d,g Proteins 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108700004049 glycosylated serum Proteins 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 206010028197 multiple epiphyseal dysplasia Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1050310 | 2010-03-31 | ||
| SE1050310-0 | 2010-03-31 | ||
| PCT/SE2011/050369 WO2011123044A1 (en) | 2010-03-31 | 2011-03-30 | Method to detect tissue degradation leading to inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013524213A true JP2013524213A (ja) | 2013-06-17 |
| JP2013524213A5 JP2013524213A5 (enExample) | 2014-05-08 |
Family
ID=44712493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502539A Pending JP2013524213A (ja) | 2010-03-31 | 2011-03-30 | 炎症をもたらす組織分解を検出する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130084584A1 (enExample) |
| EP (1) | EP2553465A4 (enExample) |
| JP (1) | JP2013524213A (enExample) |
| AU (1) | AU2011233753A1 (enExample) |
| WO (1) | WO2011123044A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3771468A1 (en) * | 2019-07-31 | 2021-02-03 | Universitätsklinikum Hamburg-Eppendorf | C3/c5 convertase assays |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63109371A (ja) * | 1986-10-16 | 1988-05-14 | バソカー | 免疫複合体のアツセイ |
| WO2001038876A1 (en) * | 1999-11-22 | 2001-05-31 | Anamar Medical Ab | Sandwich immunoassay and monoclonal antibodies for comp, cartillage oligomeric matrix protein |
| JP2006510005A (ja) * | 2002-11-08 | 2006-03-23 | バーンズ − ジューウィッシュ・ホスピタル | 非連結コラーゲン合成および分解測定法 |
| WO2008154251A2 (en) * | 2007-06-07 | 2008-12-18 | Genentech, Inc. | C3b antibodies and methods for the prevention and treatment of complement- associated disorders |
| WO2008156865A2 (en) * | 2007-06-20 | 2008-12-24 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) * | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4642284A (en) * | 1983-06-13 | 1987-02-10 | Scripps Clinic And Research Foundation | Method and system for detection of complement pathway activation |
| SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| EP0888551A1 (en) * | 1996-03-19 | 1999-01-07 | Akzo Nobel N.V. | Method for predicting the outcome of hepatitis b infection |
| EP1766411B1 (en) * | 2004-05-24 | 2011-02-23 | AnaMar AB | Method for determining a tissue degradation process by detection of comp neoepitopes |
| EP2307451B1 (en) * | 2008-03-21 | 2016-05-25 | Universiteit Hasselt | Biomarkers for rheumatoid arthritis |
-
2011
- 2011-03-30 AU AU2011233753A patent/AU2011233753A1/en not_active Abandoned
- 2011-03-30 WO PCT/SE2011/050369 patent/WO2011123044A1/en not_active Ceased
- 2011-03-30 US US13/636,145 patent/US20130084584A1/en not_active Abandoned
- 2011-03-30 JP JP2013502539A patent/JP2013524213A/ja active Pending
- 2011-03-30 EP EP11763156.4A patent/EP2553465A4/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63109371A (ja) * | 1986-10-16 | 1988-05-14 | バソカー | 免疫複合体のアツセイ |
| WO2001038876A1 (en) * | 1999-11-22 | 2001-05-31 | Anamar Medical Ab | Sandwich immunoassay and monoclonal antibodies for comp, cartillage oligomeric matrix protein |
| JP2006510005A (ja) * | 2002-11-08 | 2006-03-23 | バーンズ − ジューウィッシュ・ホスピタル | 非連結コラーゲン合成および分解測定法 |
| WO2008154251A2 (en) * | 2007-06-07 | 2008-12-18 | Genentech, Inc. | C3b antibodies and methods for the prevention and treatment of complement- associated disorders |
| WO2008156865A2 (en) * | 2007-06-20 | 2008-12-24 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
Non-Patent Citations (1)
| Title |
|---|
| JPN6014046842; Ｔ． ＳＡＸＮＥ ａｎｄ Ｄ． ＨＥＩＮＥＧＡＲＤ: Ｂｒｉｔｉｓｈ ｊｏｕｒｎａｌ ｏｆ Ｒｈｅｕｍａｔｏｌｏｇｙ Ｖｏｌ．３１，Ｎｏ．９, 1992, Ｐ．５８３-５９１ * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011233753A1 (en) | 2012-09-13 |
| WO2011123044A1 (en) | 2011-10-06 |
| US20130084584A1 (en) | 2013-04-04 |
| EP2553465A1 (en) | 2013-02-06 |
| EP2553465A4 (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7441662B2 (ja) | ｐＫａｌ関連疾病の評価、アッセイおよび治療 | |
| US20240103018A1 (en) | Galectin-3 immunoassay | |
| JP2015108635A (ja) | 線維症バイオマーカアッセイ | |
| JP3517652B2 (ja) | 中枢神経系の損傷を検出するためのアッセイ | |
| JP2014521098A (ja) | 病理学バイオマーカーアッセイ | |
| CN104024858A (zh) | 预测心血管风险的诊断试验 | |
| JP7317379B2 (ja) | 潰瘍性大腸炎及び原発性硬化性胆管炎の検査方法 | |
| US20260023079A1 (en) | Complement c4d assay | |
| JP4621593B2 (ja) | フォンヴィルブランド因子分解酵素の測定による血栓症の検出方法 | |
| CN110462404A (zh) | 测试受试者患有胰腺癌的可能性的方法 | |
| US20170097352A1 (en) | Immunoglobulin-bound extracellular vesicles and uses thereof | |
| CN115125287A (zh) | 受试者中的心血管疾病发病风险和血管钙化的判定方法及检查试剂盒 | |
| US20130084584A1 (en) | Method to detect tissue degradation leading to inflammation | |
| CN108139404A (zh) | 特异性地识别、结合活性结构的REIC/Dkk-3蛋白的抗体、以及使用该抗REIC/Dkk-3抗体的癌治疗的监测 | |
| CN114341643B (zh) | 用于测量血浆样品中功能性c1-酯酶抑制剂(c1-inh)的侧向流免疫测定 | |
| JP2011038858A (ja) | 血栓症の早期診断のための検査方法と検査試薬およびキット | |
| JP7640168B2 (ja) | 夜尿症の患者の治療応答を予測する方法 | |
| JP5640271B2 (ja) | 新規ペプチド及びその使用 | |
| JP2020046412A (ja) | ＩｇＧ４関連疾患の検査方法 | |
| JP6093943B2 (ja) | 急性冠症候群のマーカー及びその利用 | |
| HK40072995A (en) | Galectin-3 immunoassay | |
| JP2023525219A (ja) | タンパク質－アルギニンデイミナーゼ１（ｐａｄ１）自己抗原を使用する関節リウマチの診断及び評価のための組成物及び方法 | |
| JP2013064616A (ja) | 高度動脈硬化を発症している可能性を検出する方法およびその利用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140319 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140319 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141031 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150109 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150302 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150320 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150430 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150820 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160318 |